{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:14:06Z","timestamp":1790745246875,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jaci.2019.06.010","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T16:23:47Z","timestamp":1561393427000},"page":"381-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018"],"prefix":"10.1016","volume":"144","author":[{"given":"Rachel L.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Shtessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacey B.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2019.06.010_bib1","doi-asserted-by":"crossref","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global increase and geographic convergence in antibiotic consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2019.06.010_bib2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaip.2018.11.023","article-title":"Drug hypersensitivity reactions documented in electronic health records within a large health system","volume":"7","author":"Wong","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jamia\/ocx139","article-title":"A value set for documenting adverse reactions in electronic health records","volume":"25","author":"Goss","year":"2018","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.jaci.2019.06.010_bib4","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/all.13440","article-title":"Multiple drug intolerance syndrome and multiple drug allergy syndrome: epidemiology and associations with anxiety and depression","volume":"73","author":"Blumenthal","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaip.2018.09.003","article-title":"Antibiotic allergy labels in children are associated with adverse clinical outcomes","volume":"7","author":"Lucas","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000488857","article-title":"Hospitalizations in children with a penicillin allergy label: an assessment of healthcare impact","volume":"176","author":"Sousa-Pinto","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cid\/ciy037","article-title":"The impact of reported beta-lactam allergy in hospitalized patients with hematologic malignancies requiring antibiotics","volume":"67","author":"Huang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2019.06.010_bib8","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jaip.2017.12.033","article-title":"The cost of self-reported penicillin allergy: a systematic review","volume":"6","author":"Mattingly","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib9","doi-asserted-by":"crossref","first-page":"k2400","DOI":"10.1136\/bmj.k2400","article-title":"Risk of methicillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study","volume":"361","author":"Blumenthal","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2019.06.010_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/cid\/cix794","article-title":"The impact of a reported penicillin allergy on surgical site infection risk","volume":"66","author":"Blumenthal","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2019.06.010_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaci.2017.01.020","article-title":"Beta-lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/acs.chemrestox.7b00330","article-title":"Up-regulation of T-cell activation microRNAs in drug-specific CD4(+) T-Cells from hypersensitive patients","volume":"31","author":"Monroy-Arreola","year":"2018","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jaci.2019.06.010_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2010.09.009","article-title":"MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development","volume":"33","author":"O'Connell","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2019.06.010_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2017.08.009","article-title":"Use of the basophil activation test may reduce the need for drug provocation in amoxicillin-clavulanic allergy","volume":"6","author":"Salas","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib15","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jaip.2017.12.001","article-title":"The basophil activation test can be of value for diagnosing immediate allergic reactions to omeprazole","volume":"6","author":"Laguna","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib16","doi-asserted-by":"crossref","first-page":"ofy106","DOI":"10.1093\/ofid\/ofy106","article-title":"Improving aztreonam stewardship and cost through a penicillin allergy testing clinical guideline","volume":"5","author":"Chen","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jaci.2019.06.010_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaip.2017.08.006","article-title":"The cost of penicillin allergy evaluation","volume":"6","author":"Blumenthal","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jaip.2017.10.008","article-title":"Natural history of benign nonimmediate allergy to beta-lactams in children: a prospective study in retreated patients after a positive and a negative provocation test","volume":"6","author":"Tonson la Tour","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib19","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jaip.2018.04.038","article-title":"The use of telemedicine for penicillin allergy skin testing","volume":"6","author":"Staicu","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib20","doi-asserted-by":"crossref","first-page":"ofy306","DOI":"10.1093\/ofid\/ofy306","article-title":"The safety and efficacy of an oral penicillin challenge program in cancer patients: a multicenter pilot study","volume":"5","author":"Trubiano","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jaci.2019.06.010_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaip.2018.05.008","article-title":"Safety and outcomes of oral graded challenges to amoxicillin without prior skin testing","volume":"7","author":"Iammatteo","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib22","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.jaci.2018.01.031","article-title":"Chronic inducible urticaria: a systematic review of treatment options","volume":"141","author":"Dressler","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","article-title":"The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaip.2017.06.002","article-title":"Evaluation of a guidelines-based approach to the treatment of chronic spontaneous urticaria","volume":"6","author":"Sanchez","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jaip.2018.02.024","article-title":"Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria","volume":"6","author":"Deza","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13023-018-0815-5","article-title":"Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies","volume":"13","author":"Aygoren-Pursun","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaci.2019.06.010_bib28","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/all.13384","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2017 revision and update","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib29","author":"Pharming Group NV"},{"key":"10.1016\/j.jaci.2019.06.010_bib33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/all.13582","article-title":"Gene therapy for C1 esterase inhibitor deficiency in a murine model of hereditary angioedema","volume":"74","author":"Qiu","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib36","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jaci.2017.08.046","article-title":"The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions","volume":"142","author":"Yamani","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib37","first-page":"141","article-title":"Improving anaphylaxis care: the impact of a clinical pathway","author":"Lee","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2019.06.010_bib38","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaci.2017.11.053","article-title":"Basophils from allergic patients are neither hyperresponsive to activation signals nor hyporesponsive to inhibition signals","volume":"142","author":"Cassard","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.alit.2018.05.011","article-title":"Natural course of new-onset urticaria: results of a 10-year follow-up, nationwide, population-based study","volume":"68","author":"Eun","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2019.06.010_bib40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2017.07.012","article-title":"Recurrence of chronic urticaria: incidence and associated factors","volume":"6","author":"Kim","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1684\/ejd.2018.3446","article-title":"The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study)","volume":"28","author":"Lacour","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2019.06.010_bib42","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jaci.2018.05.019","article-title":"Auto-antibodies to IgE and FCeRI and the natural variability of SYK expression in basophils","volume":"143","author":"MacGlashan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib43","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2017.10.035","article-title":"IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria","volume":"142","author":"Schmetzer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib44","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/all.13352","article-title":"C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria","volume":"73","author":"Kolkhir","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib45","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jaci.2018.02.021","article-title":"Basophil FCR\u03b5RI expression is linked to time to omalizumab response in chronic spontaneous urticaria","volume":"141","author":"Deza","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaip.2017.06.023","article-title":"Chronic urticaria patient perspective (CUPP): the first validated tool for assessing quality of life in clinical practice","volume":"6","author":"Baiardini","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/all.13271","article-title":"Comparison and interpretability of the available urticaria activity scores","volume":"73","author":"Hawro","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib48","article-title":"Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \u201creal-world\u201d evidence","author":"Tharp","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2019.06.010_bib49","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.jaci.2018.07.032","article-title":"Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria","volume":"142","author":"Niemeyer-van der Kolk","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib50","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaip.2018.04.003","article-title":"Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis","volume":"6","author":"Ferrer","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaci.2018.08.050","article-title":"Real-life treatment of cholinergic urticaria with omalizumab","volume":"143","author":"Altrichter","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib52","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","article-title":"Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review","volume":"6","author":"Kulthanan","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib53","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13023-015-0233-x","article-title":"A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy","volume":"10","author":"Zanichelli","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaci.2019.06.010_bib55","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2500\/aap.2018.39.4123","article-title":"Hereditary angioedema from the patient's perspective: a follow-up patient survey","volume":"39","author":"Banerji","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2019.06.010_bib56","article-title":"Consequences of misdiagnosed and mismanaged hereditary angioedema laryngeal attacks:aAn overview of cases from the Romanian registry","volume":"2018","author":"Moldovan","year":"2018","journal-title":"Case Rep Emerg Med"},{"key":"10.1016\/j.jaci.2019.06.010_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13601-018-0229-4","article-title":"Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey","volume":"8","author":"Zanichelli","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib58","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jaip.2018.05.036","article-title":"Hereditary angioedema: clinical presentation and socioeconomic cost of 200 French patients","volume":"7","author":"Javaud","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fmed.2018.00022","article-title":"Hereditary angioedema: the economics of treatment of an orphan disease","volume":"5","author":"Lumry","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2019.06.010_bib60","doi-asserted-by":"crossref","first-page":"AB47","DOI":"10.1016\/j.jaci.2017.12.154","article-title":"Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study [abstract]","volume":"141","author":"Lumry","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib61","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","article-title":"Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema","volume":"6","author":"Lumry","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib62","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/all.13466","article-title":"Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study","volume":"73","author":"Riedl","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib63","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jaip.2018.11.042","article-title":"Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States","volume":"7","author":"Busse","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib64","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaip.2018.04.022","article-title":"Angioedema due to bradykinin dysregulation","volume":"6","author":"Cicardi","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib65","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jaci.2018.01.015","article-title":"Hereditary angioedema with normal C1 inhibitor: four types and counting","volume":"141","author":"Zuraw","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbrc.2017.12.060","article-title":"A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor","volume":"498","author":"Dewald","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2019.06.010_bib67","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/all.13270","article-title":"Hereditary angioedema with a mutation in the plasminogen gene","volume":"73","author":"Bork","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib68","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","article-title":"Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema","volume":"141","author":"Bafunno","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib69","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gene.2018.05.029","article-title":"Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency","volume":"667","author":"Loules","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.jaci.2019.06.010_bib70","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fmed.2017.00206","article-title":"The search for biomarkers in hereditary angioedema","volume":"4","author":"Kaplan","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.jaci.2019.06.010_bib71","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/cea.13219","article-title":"Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema","volume":"48","author":"Lara-Marquez","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2019.06.010_bib72","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.6061\/clinics\/2018\/e354","article-title":"Improving the management of hereditary angioedema","volume":"73","author":"Giavina-Bianchi","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.jaci.2019.06.010_bib73","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","article-title":"Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks","volume":"124","author":"Craig","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib74","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","article-title":"EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema","volume":"104","author":"Levy","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib75","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","article-title":"Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial","volume":"107","author":"Lumry","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.anai.2013.12.004","article-title":"Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial","volume":"112","author":"Riedl","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib77","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2500\/aap.2018.39.4164","article-title":"Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial","volume":"39","author":"Li","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2019.06.010_bib78","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of Lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2019.06.010_bib79","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Aygoren-Pursun","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.06.010_bib80","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12016-015-8503-x","article-title":"The epidemiology of anaphylaxis","volume":"54","author":"Yu","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib81","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40413-018-0202-7","article-title":"Increasing trends of anaphylaxis-related events: an analysis of anaphylaxis using nationwide data in Taiwan, 2001-2013","volume":"11","author":"Yao","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2019.06.010_bib82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13223-018-0251-z","article-title":"A population-based epidemiological study of anaphylaxis using national big data in Korea: trends in age-specific prevalence and epinephrine use in 2010-2014","volume":"14","author":"Jeong","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib83","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/pai.12908","article-title":"National trends in emergency department visits and hospitalizations for food-induced anaphylaxis in US children","volume":"29","author":"Motosue","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaip.2018.06.010","article-title":"Drug-induced anaphylaxis documented in electronic health records","volume":"7","author":"Dhopeshwarkar","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib85","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jaci.2017.09.012","article-title":"Self-reported adverse food reactions and anaphylaxis in the SchoolNuts study: a population-based study of adolescents","volume":"141","author":"McWilliam","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib86","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib87","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jaci.2017.08.047","article-title":"Specific IgE to gelatin as a cause of anaphylaxis to zoster vaccine","volume":"141","author":"Retterer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib88","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jaci.2017.10.043","article-title":"The transcription factors GATA2 and microphthalmia-associated transcription factor regulate Hdc gene expression in mast cells and are required for IgE\/mast cell-mediated anaphylaxis","volume":"142","author":"Li","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib89","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.jaci.2018.08.053","article-title":"Mast cell corticotropin-releasing factor subtype 2 suppresses mast cell degranulation and limits the severity of anaphylaxis and stress-induced intestinal permeability","volume":"143","author":"D'Costa","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib90","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1074\/jbc.RA118.005532","article-title":"Syntaxin 3, but not syntaxin 4, is required for mast cell regulated exocytosis, where it plays a primary role mediating compound exocytosis","volume":"294","author":"Sanchez","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2019.06.010_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aam9841","article-title":"Dysregulated invertebrate tropomyosin-dectin-1 interaction confers susceptibility to allergic diseases","volume":"3","author":"Gour","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib92","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaci.2017.07.040","article-title":"Mast cell exosomes can suppress allergic reactions by binding to IgE","volume":"141","author":"Xie","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib93","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jaci.2017.06.045","article-title":"MicroRNA-4443 regulates mast cell activation by T cell-derived microvesicles","volume":"141","author":"Shefler","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib94","first-page":"362","article-title":"Perivascular dendritic cells elicit anaphylaxis by relaying allergens to mast cells via microvesicles","author":"Choi","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaci.2019.06.010_bib95","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2017.05.027","article-title":"Anti-Fc\u03b3RIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of Fc\u03b3RIII","volume":"141","author":"Clay","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan5997","article-title":"Platelets expressing IgG receptor FcgammaRIIA\/CD32A determine the severity of experimental anaphylaxis","volume":"3","author":"Beutier","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib97","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2018.01.043","article-title":"Mast cell activation test in the diagnosis of allergic disease and anaphylaxis","volume":"142","author":"Bahri","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jbi.2018.09.012","article-title":"Predicting of anaphylaxis in big data EMR by exploring machine learning approaches","volume":"87","author":"Segura-Bedmar","year":"2018","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jaci.2019.06.010_bib99","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/pds.4645","article-title":"Evaluating automated approaches to anaphylaxis case classification using unstructured data from the FDA Sentinel System","volume":"27","author":"Ball","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaci.2019.06.010_bib100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.anai.2018.06.010","article-title":"Epinephrine auto-injector carriage and use practices among US children, adolescents, and adults","volume":"121","author":"Warren","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2019.06.010_bib101","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jaip.2018.06.025","article-title":"Patterns of carriage of prescribed adrenaline autoinjectors in 10- to 14-year-old food-allergic students: a population-based study","volume":"7","author":"Robinson","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib102","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaip.2018.01.019","article-title":"Value of a second dose of epinephrine during anaphylaxis: a patient\/caregiver survey","volume":"6","author":"Song","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.06.010_bib103","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/josh.12620","article-title":"Barriers to the administration of epinephrine in schools","volume":"88","author":"Hogue","year":"2018","journal-title":"J Sch Health"},{"key":"10.1016\/j.jaci.2019.06.010_bib104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00431-018-3246-3","article-title":"Use of epinephrine in emergency department depends on anaphylaxis severity in children","volume":"178","author":"Dubus","year":"2019","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaci.2019.06.010_bib105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.anai.2018.03.018","article-title":"Anaphylaxis care guidelines and the effect on health care resource use in the United States","volume":"121","author":"Song","year":"2018","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919308218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919308218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:21:42Z","timestamp":1758792102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674919308218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0091674919308218"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.06.010","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}